.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH05_Linagliptin.Linagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH05_Linagliptin.Linagliptin| name: | Linagliptin |
| ATC code: | A10BH05 | route: | oral |
| n-compartments | 2 |
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. It helps to improve glycaemic control by increasing incretin levels, thereby stimulating insulin release and decreasing glucagon secretion. Linagliptin is approved and widely used today for the management of type 2 diabetes.
Pharmacokinetics reported for healthy adult subjects (both males and females), after single oral administration.
Ceriello, A, & Inagaki, N (2017). Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. Journal of diabetes investigation 8(1) 19–28. DOI:10.1111/jdi.12528 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27180612
Forst, T, & Pfützner, A (2012). Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert opinion on pharmacotherapy 13(1) 101–110. DOI:10.1517/14656566.2012.642863 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149370
Retlich, S, et al., & Graefe-Mody, U (2010). Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clinical pharmacokinetics 49(12) 829–840. DOI:10.2165/11536620-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21053992